Inhibiting the HIV Integration Process: Past, Present, and the Future

HIV integrase (IN) catalyzes the insertion into the genome of the infected human cell of viral DNA produced by the retrotranscription process. The discovery of raltegravir validated the existence of the IN, which is a new target in the field of anti-HIV drug research. The mechanism of catalysis of IN is depicted, and the characteristics of the inhibitors of the catalytic site of this viral enzyme are reported. The role played by the resistance is elucidated, as well as the possibility of bypassing this problem. New approaches to block the integration process are depicted as future perspectives, such as development of allosteric IN inhibitors, dual inhibitors targeting both IN and other enzymes, inhibitors of enzymes that activate IN, activators of IN activity, as well as a gene therapy approach.

[1]  Cameron J. Schweitzer,et al.  Proteomic analysis of early HIV-1 nucleoprotein complexes. , 2013, Journal of proteome research.

[2]  D. Margolis,et al.  Prospects for Treatment of Latent HIV , 2013, Clinical pharmacology and therapeutics.

[3]  M. Humbert,et al.  Phage display-directed discovery of LEDGF/p75 binding cyclic peptide inhibitors of HIV replication. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  G. Giannini,et al.  Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. , 2012, Future medicinal chemistry.

[5]  Thomas S. Peat,et al.  Small Molecule Inhibitors of the LEDGF Site of Human Immunodeficiency Virus Integrase Identified by Fragment Screening and Structure Based Design , 2012, PloS one.

[6]  R. Chandra,et al.  Inhibition of HIV-1 Integrase gene expression by 10-23 DNAzyme , 2012, Journal of Biosciences.

[7]  Guixia Liu,et al.  Identification of old drugs as potential inhibitors of HIV-1 integrase – human LEDGF/p75 interaction via molecular docking , 2012, Journal of Molecular Modeling.

[8]  Stephen M. Shaw,et al.  Small-Molecule Inhibitors of the LEDGF/p75 Binding Site of Integrase Block HIV Replication and Modulate Integrase Multimerization , 2012, Antimicrobial Agents and Chemotherapy.

[9]  P. Cherepanov,et al.  3′-Processing and strand transfer catalysed by retroviral integrase in crystallo , 2012, The EMBO journal.

[10]  Cristina Tintori,et al.  Discovery of small molecule HIV-1 integrase dimerization inhibitors. , 2012, Bioorganic & medicinal chemistry letters.

[11]  Xiaohong Liu,et al.  New Class of HIV-1 Integrase (IN) Inhibitors with a Dual Mode of Action , 2012, The Journal of Biological Chemistry.

[12]  I. Boros,et al.  Elevated level of lysine 9‐acetylated histone H3 at the MDR1 promoter in multidrug‐resistant cells , 2012, Cancer science.

[13]  A. Engelman,et al.  Multimode, Cooperative Mechanism of Action of Allosteric HIV-1 Integrase Inhibitors* , 2012, The Journal of Biological Chemistry.

[14]  C. Katlama,et al.  Dolutegravir for the treatment of HIV , 2012, Expert opinion on investigational drugs.

[15]  F. Bushman,et al.  LEDGF/p75-Independent HIV-1 Replication Demonstrates a Role for HRP-2 and Remains Sensitive to Inhibition by LEDGINs , 2012, PLoS pathogens.

[16]  C. Tintori,et al.  Development of an AlphaScreen-Based HIV-1 Integrase Dimerization Assay for Discovery of Novel Allosteric Inhibitors , 2012, Journal of biomolecular screening.

[17]  Benjamin Young,et al.  Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. , 2012, The Lancet. Infectious diseases.

[18]  M. Wainberg,et al.  Characterization of the R263K Mutation in HIV-1 Integrase That Confers Low-Level Resistance to the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir , 2011, Journal of Virology.

[19]  H. Benyamini,et al.  A structural model of the HIV-1 Rev-integrase complex: the molecular basis of integrase regulation by Rev. , 2011, Biochemical and biophysical research communications.

[20]  J. Newman,et al.  Crystal Structures of Novel Allosteric Peptide Inhibitors of HIV Integrase Identify New Interactions at the LEDGF Binding Site , 2011, Chembiochem : a European journal of chemical biology.

[21]  Yves Pommier,et al.  Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572) , 2011, Molecular Pharmacology.

[22]  Zeger Debyser,et al.  4-[1-(4-Fluorobenzyl)-4-hydroxy-1H-indol-3-yl]-2-hydroxy-4-oxobut-2-enoic acid as a prototype to develop dual inhibitors of HIV-1 integration process. , 2011, Antiviral research.

[23]  T. Masuda Non-Enzymatic Functions of Retroviral Integrase: The Next Target for Novel Anti-HIV Drug Development , 2011, Front. Microbio..

[24]  S. Piscitelli,et al.  Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults , 2011, AIDS.

[25]  N. Neamati,et al.  Design of HIV-1 integrase inhibitors targeting the catalytic domain as well as its interaction with LEDGF/p75: a scaffold hopping approach using salicylate and catechol groups. , 2011, Bioorganic & medicinal chemistry.

[26]  T. Seki,et al.  Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes , 2011, Antimicrobial Agents and Chemotherapy.

[27]  K. Hertogs,et al.  Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor. , 2011, Antiviral research.

[28]  K. Musier-Forsyth,et al.  FRET analysis reveals distinct conformations of IN tetramers in the presence of viral DNA or LEDGF/p75 , 2011, Nucleic acids research.

[29]  M. Wainberg,et al.  The role of unintegrated DNA in HIV infection , 2011, Retrovirology.

[30]  M. Giacca,et al.  The TRIM family protein KAP1 inhibits HIV-1 integration. , 2011, Cell host & microbe.

[31]  H. Roder,et al.  Retroviral Integrases Promote Fraying of Viral DNA Ends* , 2011, The Journal of Biological Chemistry.

[32]  Soo-Yon Rhee,et al.  HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications , 2011, The Journal of infectious diseases.

[33]  M. Kogan,et al.  HIV-1 Accessory Protein Vpr: Relevance in the pathogenesis of HIV and potential for therapeutic intervention , 2011, Retrovirology.

[34]  A. Prakash,et al.  Dual inhibition: a novel promising pharmacological approach for different disease conditions , 2011, The Journal of pharmacy and pharmacology.

[35]  Xiaohong Liu,et al.  Dithiothreitol causes HIV-1 integrase dimer dissociation while agents interacting with the integrase dimer interface promote dimer formation. , 2011, Biochemistry.

[36]  H. Benyamini,et al.  Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein. , 2010, Bioorganic & medicinal chemistry.

[37]  Shigeru Miki,et al.  In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor , 2010, Antimicrobial Agents and Chemotherapy.

[38]  Zeger Debyser,et al.  Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor. , 2010, Bioorganic & medicinal chemistry.

[39]  Maxwell D. Cummings,et al.  Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance , 2010, Proceedings of the National Academy of Sciences.

[40]  L. Stuyver,et al.  Cross-Resistance Profile Determination of Two Second-Generation HIV-1 Integrase Inhibitors Using a Panel of Recombinant Viruses Derived from Raltegravir-Treated Clinical Isolates , 2010, Antimicrobial Agents and Chemotherapy.

[41]  Y. Pommier,et al.  Peptidic HIV integrase inhibitors derived from HIV gene products: structure-activity relationship studies. , 2010, Bioorganic & medicinal chemistry.

[42]  M. Wainberg,et al.  HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays , 2010, AIDS.

[43]  A. Engelman,et al.  Structure-based modeling of the functional HIV-1 intasome and its inhibition , 2010, Proceedings of the National Academy of Sciences.

[44]  A. Friedler,et al.  Specific eradication of HIV-1 from infected cultured cells , 2010, AIDS research and therapy.

[45]  K. Uberla,et al.  The human immunodeficiency virus type 1 Rev protein: ménage à trois during the early phase of the lentiviral replication cycle. , 2010, The Journal of general virology.

[46]  A. Friedler,et al.  Stimulation of the HIV-1 integrase enzymatic activity and cDNA integration by a peptide derived from the integrase protein. , 2010, Biopolymers.

[47]  Luba Tchertanov,et al.  Resistance to HIV-1 integrase inhibitors: A structural perspective. , 2010, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[48]  Hongtao Xu,et al.  Identification of Novel Mutations Responsible for Resistance to MK-2048, a Second-Generation HIV-1 Integrase Inhibitor , 2010, Journal of Virology.

[49]  Y. Pommier,et al.  Peptide HIV-1 integrase inhibitors from HIV-1 gene products. , 2010, Journal of medicinal chemistry.

[50]  A. Marchand,et al.  Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. , 2010, Nature chemical biology.

[51]  A. Friedler,et al.  A novel role for the viral Rev protein in promoting resistance to superinfection by human immunodeficiency virus type 1. , 2010, The Journal of general virology.

[52]  S. Goff,et al.  Interactions of Host Proteins with the Murine Leukemia Virus Integrase , 2010, Viruses.

[53]  M. Parker,et al.  Crystal structure of the HIV‐1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding site , 2010, FEBS letters.

[54]  Zvi Hayouka,et al.  Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370. , 2010, Biochemical and biophysical research communications.

[55]  Youcef Mehellou,et al.  Twenty-six years of anti-HIV drug discovery: where do we stand and where do we go? , 2010, Journal of medicinal chemistry.

[56]  A. Engelman,et al.  Retroviral intasome assembly and inhibition of DNA strand transfer , 2010, Nature.

[57]  B. Clotet,et al.  The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates , 2010, AIDS.

[58]  A. Friedler,et al.  Novel regulation of HIV-1 replication and pathogenicity: Rev inhibition of integration. , 2009, Protein engineering, design & selection : PEDS.

[59]  A. Zolopa,et al.  Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[60]  E. Clercq A new drug combination therapy for treatment-naive patients with HIV-1 infection, consisting of raltegravir, emtricitabine and tenofovir disoproxil fumarate , 2009 .

[61]  C. Katlama,et al.  High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[62]  P. Frange,et al.  Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus , 2009, AIDS.

[63]  M. Wainberg,et al.  Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes , 2009, Retrovirology.

[64]  J. Darlix,et al.  Analysis of the Viral Elements Required in the Nuclear Import of HIV-1 DNA , 2009, Journal of Virology.

[65]  S. Piscitelli,et al.  Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers , 2009, Antimicrobial Agents and Chemotherapy.

[66]  A. Curran,et al.  Raltegravir, Etravirine, and Ritonavir-Boosted Darunavir: A Safe and Successful Rescue Regimen for Multidrug-Resistant HIV-1 Infection , 2009, Journal of acquired immune deficiency syndromes.

[67]  M. Kvaratskhelia,et al.  An Allosteric Mechanism for Inhibiting HIV-1 Integrase with a Small Molecule , 2009, Molecular Pharmacology.

[68]  Kerim Babaoglu,et al.  Affinities between the Binding Partners of the HIV-1 Integrase Dimer-Lens Epithelium-derived Growth Factor (IN Dimer-LEDGF) Complex , 2009, The Journal of Biological Chemistry.

[69]  M. Giacca,et al.  GCN5-dependent acetylation of HIV-1 integrase enhances viral integration , 2009, Retrovirology.

[70]  M. Giacca,et al.  GCN5-dependent acetylation of HIV-1 integrase enhances viral integration , 2009, Retrovirology.

[71]  Z. Debyser,et al.  Pharmacophore‐Based Discovery of Small‐Molecule Inhibitors of Protein–Protein Interactions between HIV‐1 Integrase and Cellular Cofactor LEDGF/p75 , 2009, ChemMedChem.

[72]  D. Klein,et al.  Virologic Outcomes of Changing Enfuvirtide to Raltegravir in HIV-1 Patients Well Controlled on an Enfuvirtide Based Regimen: 24-Week Results of the CHEER Study , 2009, Journal of acquired immune deficiency syndromes.

[73]  W. Klaskala,et al.  Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study , 2009, AIDS.

[74]  S. Ikeda,et al.  Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors. , 2009, Journal of medicinal chemistry.

[75]  J. Rain,et al.  Lens Epithelium-derived Growth Factor/p75 Interacts with the Transposase-derived DDE Domain of PogZ* , 2009, Journal of Biological Chemistry.

[76]  C. Woodward,et al.  Integrase Interacts with Nucleoporin NUP153 To Mediate the Nuclear Import of Human Immunodeficiency Virus Type 1 , 2009, Journal of Virology.

[77]  L. Khachigian,et al.  DNAzymes and their therapeutic possibilities , 2009, Internal medicine journal.

[78]  D. Hazuda,et al.  Scintillation proximity assays for mechanistic and pharmacological analyses of HIV-1 integration. , 2009, Methods.

[79]  E. Garvey,et al.  1,3,4-Oxadiazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 2: SAR of the C5 position. , 2009, Bioorganic & medicinal chemistry letters.

[80]  E. Garvey,et al.  The use of oxadiazole and triazole substituted naphthyridines as HIV-1 integrase inhibitors. Part 1: Establishing the pharmacophore. , 2009, Bioorganic & medicinal chemistry letters.

[81]  Olga M. Klibanov,et al.  Elvitegravir, an oral HIV integrase inhibitor, for the potential treatment of HIV infection. , 2009, Current opinion in investigational drugs.

[82]  O. Wiest,et al.  Inhibition of histone deacetylases: a pharmacological approach to the treatment of non-cancer disorders. , 2009, Current topics in medicinal chemistry.

[83]  A. Friedler,et al.  Peptides Derived from HIV-1 Integrase that Bind Rev Stimulate Viral Genome Integration , 2009, PloS one.

[84]  D. Langley,et al.  The terminal (catalytic) adenosine of the HIV LTR controls the kinetics of binding and dissociation of HIV integrase strand transfer inhibitors. , 2008, Biochemistry.

[85]  R. Geleziunas,et al.  Preclinical Evaluation of GS-9160, a Novel Inhibitor of Human Immunodeficiency Virus Type 1 Integrase , 2008, Antimicrobial Agents and Chemotherapy.

[86]  Luba Tchertanov,et al.  The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation , 2008, Nucleic acids research.

[87]  A. Saïb,et al.  Integrase and integration: biochemical activities of HIV-1 integrase , 2008, Retrovirology.

[88]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[89]  F. Bailly,et al.  Design, synthesis, and biological evaluation of a series of 2-hydroxyisoquinoline-1,3(2H,4H)-diones as dual inhibitors of human immunodeficiency virus type 1 integrase and the reverse transcriptase RNase H domain. , 2008, Journal of medicinal chemistry.

[90]  V. Soriano,et al.  Resistance to integrase inhibitors. , 2007, Journal of HIV therapy.

[91]  K. Shokat,et al.  Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases , 2008, Nature chemical biology.

[92]  Hualiang Jiang,et al.  D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. , 2008, Biochemical and biophysical research communications.

[93]  Hualiang Jiang,et al.  Symmetrical 1-pyrrolidineacetamide showing anti-HIV activity through a new binding site on HIV-1 integrase , 2008, Acta Pharmacologica Sinica.

[94]  Zeger Debyser,et al.  Transportin-SR2 Imports HIV into the Nucleus , 2008, Current Biology.

[95]  K. Hertogs,et al.  Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase Inhibitors , 2008, Journal of Virology.

[96]  D. Hazuda,et al.  10-Hydroxy-7,8-dihydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-diones: potent, orally bioavailable HIV-1 integrase strand-transfer inhibitors with activity against integrase mutants. , 2008, Bioorganic & medicinal chemistry letters.

[97]  D. Hazuda,et al.  Raltegravir with optimized background therapy for resistant HIV-1 infection. , 2008, The New England journal of medicine.

[98]  Zeger Debyser,et al.  Inhibitory profile of a LEDGF/p75 peptide against HIV‐1 integrase: Insight into integrase–DNA complex formation and catalysis , 2008, FEBS letters.

[99]  Zhengqiang Wang,et al.  Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: introducing a diketoacid functionality into delavirdine. , 2008, Bioorganic & medicinal chemistry.

[100]  R. Dayam,et al.  HIV-1 integrase inhibitors: 2005-2006 update. , 2008, Medicinal research reviews.

[101]  A. Engelman,et al.  The Lentiviral Integrase Binding Protein LEDGF/p75 and HIV-1 Replication , 2008, PLoS pathogens.

[102]  Zhengqiang Wang,et al.  Synthesis of pyrimidine and quinolone conjugates as a scaffold for dual inhibitors of HIV reverse transcriptase and integrase. , 2008, Bioorganic & medicinal chemistry letters.

[103]  Luba Tchertanov,et al.  Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro , 2008, Antimicrobial Agents and Chemotherapy.

[104]  E. Garvey,et al.  The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral , 2007, Antimicrobial Agents and Chemotherapy.

[105]  M. Markowitz,et al.  Raltegravir (MK-0518): an integrase inhibitor for the treatment of HIV-1. , 2007, Drugs of today.

[106]  M. Matsuoka,et al.  Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137) , 2007, Journal of Virology.

[107]  Laith Q Al-Mawsawi,et al.  Blocking interactions between HIV-1 integrase and cellular cofactors: an emerging anti-retroviral strategy. , 2007, Trends in pharmacological sciences.

[108]  C. Crumpacker,et al.  Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study , 2007, Journal of acquired immune deficiency syndromes.

[109]  R. Benarous,et al.  Differential interaction of HIV-1 integrase and JPO2 with the C terminus of LEDGF/p75. , 2007, Journal of molecular biology.

[110]  D. Hazuda,et al.  Inhibition of Human Immunodeficiency Virus Type 1 Concerted Integration by Strand Transfer Inhibitors Which Recognize a Transient Structural Intermediate , 2007, Journal of Virology.

[111]  N. Meanwell,et al.  Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. , 2007, Current opinion in investigational drugs.

[112]  A. Engelman,et al.  LEDGF/p75 functions downstream from preintegration complex formation to effect gene-specific HIV-1 integration. , 2007, Genes & development.

[113]  C. Salomon,et al.  Rationally designed dual inhibitors of HIV reverse transcriptase and integrase. , 2007, Journal of medicinal chemistry.

[114]  Alon Herschhorn,et al.  Inhibition of the activities of reverse transcriptase and integrase of human immunodeficiency virus type-1 by peptides derived from the homologous viral protein R (Vpr). , 2007, Journal of molecular biology.

[115]  A. Friedler,et al.  Interaction between HIV-1 Rev and Integrase Proteins , 2007, Journal of Biological Chemistry.

[116]  Joseph Rosenbluh,et al.  Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium , 2007, Proceedings of the National Academy of Sciences.

[117]  Xiaojian Yao,et al.  Interaction of Human Immunodeficiency Virus Type 1 Integrase with Cellular Nuclear Import Receptor Importin 7 and Its Impact on Viral Replication* , 2007, Journal of Biological Chemistry.

[118]  C. Katlama,et al.  Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial , 2007, The Lancet.

[119]  S. Goff,et al.  Host factors exploited by retroviruses , 2007, Nature Reviews Microbiology.

[120]  E. Novellino,et al.  Cinnamoyl compounds as simple molecules that inhibit p300 histone acetyltransferase. , 2007, Journal of medicinal chemistry.

[121]  Myriam Witvrouw,et al.  Virus Evolution Reveals an Exclusive Role for LEDGF/p75 in Chromosomal Tethering of HIV , 2007, PLoS pathogens.

[122]  R. Copeland,et al.  Drug–target residence time and its implications for lead optimization , 2007, Nature Reviews Drug Discovery.

[123]  Youichi Suzuki,et al.  The road to chromatin — nuclear entry of retroviruses , 2007, Nature Reviews Microbiology.

[124]  Y. Pommier,et al.  Probing HIV-1 Integrase Inhibitor Binding Sites with Position-Specific Integrase-DNA Cross-Linking Assays , 2007, Molecular Pharmacology.

[125]  U. Koch,et al.  From dihydroxypyrimidine carboxylic acids to carboxamide HIV-1 integrase inhibitors: SAR around the amide moiety. , 2007, Bioorganic & medicinal chemistry letters.

[126]  M. Rowley,et al.  4,5-dihydroxypyrimidine carboxamides and N-alkyl-5-hydroxypyrimidinone carboxamides are potent, selective HIV integrase inhibitors with good pharmacokinetic profiles in preclinical species. , 2006, Journal of medicinal chemistry.

[127]  Wulin Teo,et al.  An Essential Role for LEDGF/p75 in HIV Integration , 2006, Science.

[128]  N. Neamati,et al.  Inhibition of HIV-1 integrase activity by synthetic peptides derived from the HIV-1 HXB2 Pol region of the viral genome. , 2006, Bioorganic & medicinal chemistry letters.

[129]  Jelle Hendrix,et al.  Overexpression of the Lens Epithelium-Derived Growth Factor/p75 Integrase Binding Domain Inhibits Human Immunodeficiency Virus Replication , 2006, Journal of Virology.

[130]  M. Horikoshi,et al.  Simple histone acetylation plays a complex role in the regulation of gene expression. , 2006, Briefings in functional genomics & proteomics.

[131]  M. Tsiang,et al.  Design, synthesis, and biological evaluation of novel tricyclic HIV-1 integrase inhibitors by modification of its pyridine ring. , 2006, Bioorganic & medicinal chemistry letters.

[132]  Myriam Witvrouw,et al.  Discovery of a small-molecule HIV-1 integrase inhibitor-binding site. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[133]  A. Engelman,et al.  Transcriptional co-activator p75 binds and tethers the Myc-interacting protein JPO2 to chromatin , 2006, Journal of Cell Science.

[134]  H. Mitsuya,et al.  Overcoming HIV drug resistance through rational drug design based on molecular, biochemical, and structural profiles of HIV resistance , 2006, Cellular and Molecular Life Sciences.

[135]  Wei Yang,et al.  Stepwise analyses of metal ions in RNase H catalysis from substrate destabilization to product release , 2006, The EMBO journal.

[136]  Y. Pommier,et al.  Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action. , 2006, Journal of medicinal chemistry.

[137]  C. Van den Haute,et al.  Transient and Stable Knockdown of the Integrase Cofactor LEDGF/p75 Reveals Its Role in the Replication Cycle of Human Immunodeficiency Virus , 2006, Journal of Virology.

[138]  Z. Debyser,et al.  Cellular co-factors of HIV-1 integration. , 2006, Trends in biochemical sciences.

[139]  J. Gervay-Hague,et al.  Current Developments in HIV Chemotherapy , 2006, ChemMedChem.

[140]  A. Engelman,et al.  Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[141]  Sylvie Garneau-Tsodikova,et al.  Protein posttranslational modifications: the chemistry of proteome diversifications. , 2005, Angewandte Chemie.

[142]  M. Emerman,et al.  The Cell Cycle Independence of HIV Infections Is Not Determined by Known Karyophilic Viral Elements , 2005, PLoS pathogens.

[143]  M. Giacca,et al.  Acetylation of HIV‐1 integrase by p300 regulates viral integration , 2005, The EMBO journal.

[144]  Myriam Witvrouw,et al.  Integrase Mutants Defective for Interaction with LEDGF/p75 Are Impaired in Chromosome Tethering and HIV-1 Replication* , 2005, Journal of Biological Chemistry.

[145]  Alon Herschhorn,et al.  Peptides Derived from the Reverse Transcriptase of Human Immunodeficiency Virus Type 1 as Novel Inhibitors of the Viral Integrase* , 2005, Journal of Biological Chemistry.

[146]  A. Engelman,et al.  Solution structure of the HIV-1 integrase-binding domain in LEDGF/p75 , 2005, Nature Structural &Molecular Biology.

[147]  Y. Pommier,et al.  Design, synthesis and biological evaluation of heteroaryl diketohexenoic and diketobutanoic acids as HIV-1 integrase inhibitors endowed with antiretroviral activity. , 2005, Farmaco.

[148]  R. Di Santo,et al.  6-[1-(4-Fluorophenyl)methyl-1H-pyrrol-2-yl)]-2,4-dioxo-5-hexenoic acid ethyl ester a novel diketo acid derivative which selectively inhibits the HIV-1 viral replication in cell culture and the ribonuclease H activity in vitro. , 2005, Antiviral research.

[149]  Marc C. Nicklaus,et al.  Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design , 2004, J. Comput. Aided Mol. Des..

[150]  Tomozumi Imamichi,et al.  Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. , 2004, Current pharmaceutical design.

[151]  Pamela A. Silver,et al.  Identification of an Evolutionarily Conserved Domain in Human Lens Epithelium-derived Growth Factor/Transcriptional Co-activator p75 (LEDGF/p75) That Binds HIV-1 Integrase* , 2004, Journal of Biological Chemistry.

[152]  Pamela A Silver,et al.  Human cell proteins and human immunodeficiency virus DNA integration. , 2004, Frontiers in bioscience : a journal and virtual library.

[153]  J. Kappes,et al.  Evidence that Stable Retroviral Transduction and Cell Survival following DNA Integration Depend on Components of the Nonhomologous End Joining Repair Pathway , 2004, Journal of Virology.

[154]  Mark Embrey,et al.  A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[155]  D. Hazuda,et al.  Integrase Inhibitors and Cellular Immunity Suppress Retroviral Replication in Rhesus Macaques , 2004, Science.

[156]  S. A. Chow,et al.  Requirement for Integrase during Reverse Transcription of Human Immunodeficiency Virus Type 1 and the Effect of Cysteine Mutations of Integrase on Its Interactions with Reverse Transcriptase , 2004, Journal of Virology.

[157]  Robert Craigie,et al.  Identification of an inhibitor-binding site to HIV-1 integrase with affinity acetylation and mass spectrometry. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[158]  G. Kalpana,et al.  Specificity of Interaction of INI1/hSNF5 with Retroviral Integrases and Its Functional Significance , 2004, Journal of Virology.

[159]  J. Mouscadet,et al.  The Human Polycomb Group EED Protein Interacts with the Integrase of Human Immunodeficiency Virus Type 1 , 2003, Journal of Virology.

[160]  E. De Clercq,et al.  Development of Resistance against Diketo Derivatives of Human Immunodeficiency Virus Type 1 by Progressive Accumulation of Integrase Mutations , 2003, Journal of Virology.

[161]  R. Malathi,et al.  Non-Watson Crick base pairs might stabilize RNA structural motifs in ribozymes — a comparative study of group-I intron structures , 2003, Journal of Biosciences.

[162]  Marc C Nicklaus,et al.  Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S). , 2003, Molecular pharmacology.

[163]  F. Bailly,et al.  Structure-activity relationships of HIV-1 integrase inhibitors--enzyme-ligand interactions. , 2003, Current medicinal chemistry.

[164]  Ian F. Harrison,et al.  Nuclear import of HIV‐1 intracellular reverse transcription complexes is mediated by importin 7 , 2003, The EMBO journal.

[165]  B. Roques,et al.  The (52-96) C-terminal domain of Vpr stimulates HIV-1 IN-mediated homologous strand transfer of mini-viral DNA. , 2003, Nucleic acids research.

[166]  M. Shultz,et al.  Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. , 2003, Bioorganic & medicinal chemistry letters.

[167]  B. Roques,et al.  NMR structure of the HIV-1 regulatory protein VPR. , 2003, Journal of molecular biology.

[168]  D. Hazuda,et al.  Inhibition of HIV-1 Ribonuclease H by a Novel Diketo Acid, 4-[5-(Benzoylamino)thien-2-yl]-2,4-dioxobutanoic Acid* , 2003, The Journal of Biological Chemistry.

[169]  Linghang Zhuang,et al.  Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. , 2003, Journal of medicinal chemistry.

[170]  Zeger Debyser,et al.  HIV-1 Integrase Forms Stable Tetramers and Associates with LEDGF/p75 Protein in Human Cells* , 2003, The Journal of Biological Chemistry.

[171]  N. Sluis-Cremer,et al.  Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. , 2002, European journal of biochemistry.

[172]  Paul Shinn,et al.  HIV-1 Integration in the Human Genome Favors Active Genes and Local Hotspots , 2002, Cell.

[173]  G. Bocharov,et al.  Recombination: Multiply infected spleen cells in HIV patients , 2002, Nature.

[174]  Jon Cohen Confronting the Limits of Success , 2002, Science.

[175]  Yun Tang,et al.  Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors. , 2002, Journal of medicinal chemistry.

[176]  A. Hizi,et al.  Inhibition of the integrases of human immunodeficiency viruses type 1 and type 2 by reverse transcriptases. , 2002, The Biochemical journal.

[177]  Wei Yang,et al.  Structure of a two‐domain fragment of HIV‐1 integrase: implications for domain organization in the intact protein , 2001, The EMBO journal.

[178]  J. Mouscadet,et al.  Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers. , 2001, Biochemistry.

[179]  G. Maga,et al.  HIV‐1 reverse transcriptase and integrase enzymes physically interact and inhibit each other , 2001, FEBS letters.

[180]  A. Banerjea,et al.  Novel mono- and di-DNA-enzymes targeted to cleave TAT or TAT-REV RNA inhibit HIV-1 gene expression. , 2001, Antiviral Research.

[181]  N. Jing,et al.  Rational drug design of DNA oligonucleotides as HIV inhibitors. , 2001, Current drug targets. Infectious disorders.

[182]  Robert Craigie,et al.  HIV Integrase, a Brief Overview from Chemistry to Therapeutics* , 2001, The Journal of Biological Chemistry.

[183]  O. Genilloud,et al.  The complestatins as HIV-1 integrase inhibitors. Efficient isolation, structure elucidation, and inhibitory activities of isocomplestatin, chloropeptin I, new complestatins, A and B, and acid-hydrolysis products of chloropeptin I. , 2001, Journal of natural products.

[184]  Frederic D. Bushman,et al.  A quantitative assay for HIV DNA integration in vivo , 2001, Nature Medicine.

[185]  J. Perona,et al.  Making the most of metal ions , 2001, Nature Structural Biology.

[186]  Tania A. Baker,et al.  Comparative architecture of transposase and integrase complexes , 2001, Nature Structural Biology.

[187]  G. Nabel,et al.  Viral replication and the coactivators p300 and CBP. , 2000, Trends in microbiology.

[188]  F. Bushman,et al.  Repair of Gaps in Retroviral DNA Integration Intermediates , 2000, Journal of Virology.

[189]  Amy S. Espeseth,et al.  HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[190]  Y. Pommier,et al.  Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. , 2000, Molecular pharmacology.

[191]  R M Stroud,et al.  Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[192]  J A Grobler,et al.  Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. , 2000, Science.

[193]  L. Chylack,et al.  Lens epithelium-derived growth factor: effects on growth and survival of lens epithelial cells, keratinocytes, and fibroblasts. , 2000, Biochemical and biophysical research communications.

[194]  P. Brown,et al.  Stereospecificity of Reactions Catalyzed by HIV-1 Integrase* , 1999, The Journal of Biological Chemistry.

[195]  G. Cohen,et al.  Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[196]  T. Steitz DNA Polymerases: Structural Diversity and Common Mechanisms* , 1999, The Journal of Biological Chemistry.

[197]  Patrick L. Hindmarsh,et al.  HMG Protein Family Members Stimulate Human Immunodeficiency Virus Type 1 and Avian Sarcoma Virus Concerted DNA Integration In Vitro , 1999, Journal of Virology.

[198]  A. Gronenborn,et al.  Solution structure of the His 12 → Cys mutant of the N‐terminal zinc binding domain of HIV‐1 integrase complexed to cadmium , 1998, Protein science : a publication of the Protein Society.

[199]  E. Novellino,et al.  Geometrically and conformationally restrained cinnamoyl compounds as inhibitors of HIV-1 integrase: synthesis, biological evaluation, and molecular modeling. , 1998, Journal of medicinal chemistry.

[200]  D. Davies,et al.  Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[201]  F. Bushman,et al.  Chromosome Structure and Human Immunodeficiency Virus Type 1 cDNA Integration: Centromeric Alphoid Repeats Are a Disfavored Target , 1998, Journal of Virology.

[202]  F. Bushman,et al.  Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition , 1997, Journal of virology.

[203]  R. Siliciano,et al.  Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection , 1997, Nature.

[204]  F. Bushman,et al.  HIV-1 cDNA Integration: Requirement of HMG I(Y) Protein for Function of Preintegration Complexes In Vitro , 1997, Cell.

[205]  Y. Pommier,et al.  Chemical Trapping of Ternary Complexes of Human Immunodeficiency Virus Type 1 Integrase, Divalent Metal, and DNA Substrates Containing an Abasic Site , 1996, The Journal of Biological Chemistry.

[206]  S. Sarafianos,et al.  Biochemical analysis of catalytically crucial aspartate mutants of human immunodeficiency virus type 1 reverse transcriptase. , 1996, Biochemistry.

[207]  H. Buc,et al.  The Metal Ion-induced Cooperative Binding of HIV-1 Integrase to DNA Exhibits a Marked Preference for Mn(II) Rather than Mg(II) (*) , 1996, The Journal of Biological Chemistry.

[208]  Y. Pommier,et al.  Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase. , 1995, Biochemistry.

[209]  A M Gronenborn,et al.  Solution structure of the DNA binding domain of HIV-1 integrase. , 1995, Biochemistry.

[210]  A. Engelman,et al.  Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication , 1995, Journal of virology.

[211]  G. Crabtree,et al.  Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. , 1994, Science.

[212]  A. Engelman,et al.  Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. , 1994, Science.

[213]  R R Breaker,et al.  A DNA enzyme that cleaves RNA. , 1994, Chemistry & biology.

[214]  M. Emerman,et al.  The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[215]  J. Steitz,et al.  A general two-metal-ion mechanism for catalytic RNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[216]  M. Bukrinsky,et al.  Association of integrase, matrix, and reverse transcriptase antigens of human immunodeficiency virus type 1 with viral nucleic acids following acute infection. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[217]  Robert Craigie,et al.  HIV-1 DNA integration: Mechanism of viral DNA cleavage and DNA strand transfer , 1991, Cell.

[218]  R. Plasterk,et al.  Human immunodeficiency virus integrase protein requires a subterminal position of its viral DNA recognition sequence for efficient cleavage , 1991, Journal of virology.

[219]  F. Bushman,et al.  A rapid in vitro assay for HIV DNA integration. , 1991, Nucleic acids research.

[220]  W. Haseltine,et al.  Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex , 1991, Journal of virology.

[221]  T. Steitz,et al.  Structural basis for the 3′‐5′ exonuclease activity of Escherichia coli DNA polymerase I: a two metal ion mechanism. , 1991, The EMBO journal.

[222]  F. Bushman,et al.  Retroviral DNA integration directed by HIV integration protein in vitro. , 1990, Science.

[223]  P. Brown,et al.  Human immunodeficiency virus integration in a cell-free system , 1990, Journal of virology.

[224]  H. Masur,et al.  An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. , 1981, The New England journal of medicine.

[225]  M. Gottlieb,et al.  Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. , 1981, The New England journal of medicine.

[226]  C. Cunningham-Rundles,et al.  Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. , 1981, The New England journal of medicine.

[227]  F. Muregi,et al.  Novel rational drug design strategies with potential to revolutionize malaria chemotherapy. , 2011, Current medicinal chemistry.

[228]  A. Friedler,et al.  Integration of HIV-1 DNA Is Regulated by Interplay between Viral Rev and Cellular LEDGF/p75 Proteins , 2010, Molecular medicine.

[229]  Xiaowu Chen,et al.  Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. , 2010, Antiviral research.

[230]  A. Friedler,et al.  Peptides derived from HIV‐1 Rev inhibit HIV‐1 integrase in a shiftide mechanism , 2008, Biopolymers.

[231]  E. De Clercq New approaches toward anti-HIV chemotherapy. , 2005, Journal of medicinal chemistry.

[232]  E. Zubin,et al.  HIV-1 integrase can process a 3'-end crosslinked substrate. , 2004, European journal of biochemistry.

[233]  Y. Pommier,et al.  Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. , 2002, The Journal of biological chemistry.

[234]  Y. Pommier,et al.  In vitro human immunodeficiency virus type 1 integrase assays. , 2001, Methods in enzymology.